This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1989;25(1):1-9.

doi: 10.1007/BF00694330.

Cisplatin nephrotoxicity. A review

G Daugaard¹, U Abildgaard

Affiliations

PMID: 2686850
DOI: 10.1007/BF00694330

Review

Cisplatin nephrotoxicity. A review

G Daugaard et al. Cancer Chemother Pharmacol. 1989.

. 1989;25(1):1-9.

doi: 10.1007/BF00694330.

Authors

G Daugaard¹, U Abildgaard

Affiliation

¹ Department of Oncology ONB, Rigshospitalet, Copenhagen, Denmark.

PMID: 2686850
DOI: 10.1007/BF00694330

No abstract available

PubMed Disclaimer

Similar articles

Effects of a DPP4 inhibitor on cisplatin-induced acute kidney injury: study protocol for a randomized controlled trial.
Baek SH, Kim SH, Kim JW, Kim YJ, Lee KW, Na KY. Baek SH, et al. Trials. 2015 May 29;16:239. doi: 10.1186/s13063-015-0772-4. Trials. 2015. PMID: 26021829 Free PMC article. Clinical Trial.
Estimation versus measurement of the glomerular filtration rate for kidney function assessment in patients with cancer undergoing cisplatin-based chemotherapy.
Klöckl MC, Kasparek AK, Riedl JM, Moik F, Mollnar S, Stotz M, Szkandera J, Terbuch A, Gerger A, Niedrist T, Pichler M, Bauernhofer T, Schilcher G, Zitta S, Rosenkranz AR, Friedl C, Stöger H, Posch F. Klöckl MC, et al. Sci Rep. 2020 Jul 8;10(1):11219. doi: 10.1038/s41598-020-68010-5. Sci Rep. 2020. PMID: 32641710 Free PMC article.
Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients.
Ishitsuka R, Miyazaki J, Ichioka D, Inoue T, Kageyama S, Sugimoto M, Mitsuzuka K, Matsui Y, Shiraishi Y, Kinoshita H, Wakeda H, Nomoto T, Kikuchi E, Kawai K, Nishiyama H. Ishitsuka R, et al. Clin Exp Nephrol. 2017 Aug;21(4):732-740. doi: 10.1007/s10157-016-1327-z. Epub 2016 Aug 26. Clin Exp Nephrol. 2017. PMID: 27565169
Nephrotoxicity of anticancer treatment.
Malyszko J, Kozlowska K, Kozlowski L, Malyszko J. Malyszko J, et al. Nephrol Dial Transplant. 2017 Jun 1;32(6):924-936. doi: 10.1093/ndt/gfw338. Nephrol Dial Transplant. 2017. PMID: 28339935 Review.
Identifying cisplatin-induced kidney damage in paediatric oncology patients.
Barton CD, Pizer B, Jones C, Oni L, Pirmohamed M, Hawcutt DB. Barton CD, et al. Pediatr Nephrol. 2018 Sep;33(9):1467-1474. doi: 10.1007/s00467-017-3765-6. Epub 2017 Aug 18. Pediatr Nephrol. 2018. PMID: 28821959 Free PMC article. Review.

See all similar articles

Cited by

Physalis alkekengi and Alhagi maurorum ameliorate the side effect of cisplatin-induced nephrotoxicity.
Changizi-Ashtiyani S, Alizadeh M, Najafi H, Babaei S, Khazaei M, Jafari M, Hossaini N, Avan A, Bastani B. Changizi-Ashtiyani S, et al. Cancer Gene Ther. 2016 Jul;23(7):235-40. doi: 10.1038/cgt.2016.24. Epub 2016 Jun 3. Cancer Gene Ther. 2016. PMID: 27255563
Sequence-dependent termination of mammalian DNA polymerase reaction by a new platinum compound, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutane-dicarboxylato)-2-plati num(II) monohydrate).
Iwata M, Izuta S, Suzuki M, Kojima K, Furuhashi Y, Tomoda Y, Yoshida S. Iwata M, et al. Jpn J Cancer Res. 1991 Apr;82(4):433-9. doi: 10.1111/j.1349-7006.1991.tb01867.x. Jpn J Cancer Res. 1991. PMID: 1904423 Free PMC article.
Risk factors for renal toxicity after inpatient cisplatin administration.
Galfetti E, Cerutti A, Ghielmini M, Zucca E, Wannesson L. Galfetti E, et al. BMC Pharmacol Toxicol. 2020 Mar 2;21(1):19. doi: 10.1186/s40360-020-0398-3. BMC Pharmacol Toxicol. 2020. PMID: 32122396 Free PMC article.
Comparative adverse effect profiles of platinum drugs.
McKeage MJ. McKeage MJ. Drug Saf. 1995 Oct;13(4):228-44. doi: 10.2165/00002018-199513040-00003. Drug Saf. 1995. PMID: 8573296 Review.
Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management.
Oronsky B, Caroen S, Oronsky A, Dobalian VE, Oronsky N, Lybeck M, Reid TR, Carter CA. Oronsky B, et al. Cancer Chemother Pharmacol. 2017 Nov;80(5):895-907. doi: 10.1007/s00280-017-3392-8. Epub 2017 Jul 20. Cancer Chemother Pharmacol. 2017. PMID: 28730291 Free PMC article. Review.

See all "Cited by" articles

References

1. Cancer Chemother Rep. 1973 Sep-Oct;57(3):357-9 - PubMed
1. Cancer Treat Rep. 1984 Nov;68(11):1367-73 - PubMed
1. Am J Obstet Gynecol. 1985 Nov 15;153(6):660-5 - PubMed
1. Scand J Clin Lab Invest. 1987 Sep;47(5):455-9 - PubMed
1. J Pharmacol Exp Ther. 1984 Dec;231(3):752-8 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Other Literature Sources
- The Lens - Patent Citations Database